RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer.
The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others.
Get the full story at our sister site, Drug Delivery Business News.
The post RenovoRx raises $7m for drug-device pancreatic cancer therapy appeared first on MassDevice.